Business Context and Reporting Period
Drugs Made In America Acquisition Corp. (DMAA), a Cayman Islands-based special purpose acquisition company (SPAC), filed this Form 8-K on January 29, 2025. The report details the consummation of its Initial Public Offering (IPO) and a concurrent private placement.
Key Financial Metrics
- IPO Proceeds: Sold 20,000,000 Units at $10.00 per Unit, generating $200,000,000 in gross proceeds.
- Private Placement: Sponsor purchased 400,000 private units at $10.00 per unit for a total of $4,000,000.
- Subscription Receivable: $1,100,000 of the private placement proceeds has not yet been received.
- Trust Account: As of January 29, 2025, $201,000,000 of net proceeds were deposited into a trust account for public shareholders.
- Revenue/Profit/Cash Flow: The filing text does not provide operating revenue, profit, or cash flow metrics as the company is in the pre-business combination stage.
Material Changes
This filing represents the commencement of the Company's public operations. The primary material change is the transition from a private entity to a publicly traded company on The Nasdaq Stock Market LLC with Units (DMAAU), Ordinary Shares (DMAA), and Rights (DMAAR) now registered.
Outlook, Risks, and Contingencies
The Company is an emerging growth company. The primary contingency noted is the outstanding subscription receivable of $1,100,000 from the sponsor's private placement. The filing does not provide specific management commentary on future business targets or detailed risk factors beyond standard SPAC structures.
Investor Verification Checklist
- Verify the final settlement of the $1,100,000 subscription receivable from the sponsor.
- Confirm the exact amount of underwriting discounts and commissions deducted from the $200,000,000 gross IPO proceeds to reconcile the $201,000,000 trust deposit.
- Review the attached Balance Sheet (Exhibit 99.1) for a complete view of working capital and liabilities.
- Monitor the timeline for the initial business combination to determine the redemption rights of public shareholders.